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a b s t r a c t
We report a novel class of carbamate-type ChE inhibitors, structural analogs of pyridostigmine. A small
library of congeneric pyridoxine-based compounds was designed, synthesized and evaluated for AChE
and BChE enzymes inhibition in vitro. The most active compounds have potent enzyme inhibiting activity
with IC50 values in the range of 0.46–2.1 lM (for AChE) and 0.59–8.1 lM (for BChE), with moderate selec-
tivity for AChE comparable with that of pyridostigmine and neostigmine. Acute toxicity studies using
mice models demonstrated excellent safety profile of the obtained compounds with LD50 in the range
of 22–326 mg/kg, while pyridostigmine and neostigmine are much more toxic (LD50 3.3 and 0.51 mg/
kg, respectively). The obtained results pave the way to design of novel potent and safe cholinesterase
inhibitors for symptomatic treatment of neuromuscular disorders.
 2016 Elsevier Ltd. All rights reserved.
Disorders of neuromuscular synaptic transmission (Myasthenia
Gravis, Lambert Eaton Syndrome and Congenital Myasthenic
Syndromes) are a group of diseases in which an abnormality of
neurotransmitter-receptor interaction or an abnormality of
neurotransmitter release at the neuromuscular junction (NMJ) pro-
vokes the muscles weakness. In many instances the diseases are
mediated by an autoantibody directed to a specific epitope at the
NMJ.1 In others, there is a genetically acquired abnormality of
the structure of the NMJ.2 While primary therapy for the majority
of the immune mediated disorders involves immunosuppressive
drugs with or without thymectomy, patients are also treated with
inhibitors of acetyl- and butyrylcholinesterase (BChE) for
symptomatic improvement of muscles weakness.3 For Congenital
Myasthenic Syndromes, medications by inhibitors of cholines-
terases (ChEs) are the standard of care.4 Effectiveness of ChEs inhi-
bition in symptomatic treatment of muscles weakness is based on
their ability to potentiate the effects of neurotransmitter acetyl-
choline (ACh) due to a decrease in the rate of its enzymatic hydrol-
ysis. When a selective acetylcholinesterase (AChE) inhibitors are
used to increase the ACh concentration in the synaptic cleft, the
functional improvement is better than with a non-selective
inhibitor of ChEs, during which inhibition of BChE counteracts
the positive action of AChE inhibition.5
Currently, the most frequently used ChEs inhibitor in treatment
of muscle weakness symptoms is pyridostigmine3 (Fig. 1). This
pseudo-reversible carbamylating agent does not cross the blood–
brain barrier, and its selectivity for human AChE is poor [Ki ratio
(BChE/AChE)  6].6 Neostigmine (Fig. 1) is another nonspecific
ChEs inhibitor. Due to strong muscarinic side effects, it is less fre-
quently used than pyridostigmine for the treatment of muscle
weaknesses.7 However, anaesthetists traditionally use neostigmine
in daily routine practice to reverse the action of nondepolarizing
muscle relaxants.8
There are serious safety concerns regarding the therapeutic use
of ChEs inhibitors.3 In particular, carbamates stimulate delayed
neuropathy or make it more severe, when they are dosed after
applying organophosphate (OP) neuropathic doses, inducing pro-
motion of delayed neuropathy.9 Thus, pyridostigmine bromide
has been FDA approved for military use during combat situations
as an agent to be given prior to exposure to the nerve agent soman
in order to increase survival. However, used in particular during
the first Gulf War, pyridostigmine itself has been implicated as a
causal factor in Gulf War syndrome.10
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